Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameJW Therap-B
Stock Code02126
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities公司為中國領先的臨床及臨床前階段細胞治療公司,專注於開發、製造和商業化用於血液癌症及實體瘤的突破性細胞免疫療法,主打候選產品為針對復發或難治B細胞淋巴瘤的自體抗CD19 CAR-T療法relma-cel。
Listing Date2020-11-03
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海自由貿易試驗區美盛路225號42號樓4樓
Business Address (Hong Kong)銅鑼灣勿地臣街1號時代廣場2座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.jwtherapeutics.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 23.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 11,900
Par ValueTo be extracted
Offer Period2020-10-22 to 2020-10-28
Global Offering Shares97,692,000 shares
HK Public Offer Shares (Initial)9,770,000 shares (10.0%)
Public Offer Lots (Initial)19,540lots (Pool A9,770lots,Pool B9,770lots)
International Placing Shares (Initial)87,922,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO376,176,229 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share50.0%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 2,325,069,600

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 11,900
2 lots 1,000 HK$ 23,800
3 lots 1,500 HK$ 35,700
4 lots 2,000 HK$ 47,600
5 lots 2,500 HK$ 59,500
6 lots 3,000 HK$ 71,400
7 lots 3,500 HK$ 83,300
8 lots 4,000 HK$ 95,200
9 lots 4,500 HK$ 107,100
10 lots 5,000 HK$ 119,000
12 lots 6,000 HK$ 142,800
14 lots 7,000 HK$ 166,600
16 lots 8,000 HK$ 190,400
18 lots 9,000 HK$ 214,200
20 lots 10,000 HK$ 238,000
30 lots 15,000 HK$ 357,000
40 lots 20,000 HK$ 476,000
50 lots 25,000 HK$ 595,000
60 lots 30,000 HK$ 714,000
70 lots 35,000 HK$ 833,000
80 lots 40,000 HK$ 952,000
90 lots 45,000 HK$ 1,071,000
100 lots 50,000 HK$ 1,190,000
120 lots 60,000 HK$ 1,428,000
140 lots 70,000 HK$ 1,666,000
160 lots 80,000 HK$ 1,904,000
180 lots 90,000 HK$ 2,142,000
200 lots 100,000 HK$ 2,380,000
400 lots 200,000 HK$ 4,760,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 300,000 HK$ 7,140,000
800 lots 400,000 HK$ 9,520,000
1,000 lots 500,000 HK$ 11,900,000
1,200 lots 600,000 HK$ 14,280,000
1,400 lots 700,000 HK$ 16,660,000
1,600 lots 800,000 HK$ 19,040,000
1,800 lots 900,000 HK$ 21,420,000
2,000 lots 1,000,000 HK$ 23,800,000
3,000 lots 1,500,000 HK$ 35,700,000
4,000 lots 2,000,000 HK$ 47,600,000
5,000 lots 2,500,000 HK$ 59,500,000
6,000 lots 3,000,000 HK$ 71,400,000
7,000 lots 3,500,000 HK$ 83,300,000
8,000 lots 4,000,000 HK$ 95,200,000
9,770 lots 4,885,000 HK$ 116,263,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 937.7M
Est. Threshold HK$ 9.44B
Analysis Result HK market cap below threshold, need +907%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,952,994,250
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣633.3百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Balance Sheet
Item 20182019
Cash and cash equivalents 4,5397,796
Total current assets 5,5039,174
Total assets 12,64214,962
Total current liabilities 21,85253,458
Total liabilities 21,85253,458
Total equity -9,210-38,496
Equity attributable to owners -9,210-38,496
Cash Flow Statement
Item 20182019
Net cash from operating activities 0-16,350
Net cash from investing activities -2,341-10,319
Net cash from financing activities 7,91830,687
Net increase in cash 5,5774,018
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 22.0
First Day OpenHK$ 24.35
First Day Change-7.56%
First Day Volume48183900.0
First Day Turnover1139990000.0
Use of Proceeds
1、約878.7百萬港元(占所得款項凈額約40.0%)預期將用于我們的核心候選產品relma-cel; 2、約746.9百萬港元(占所得款項凈額的34.0%)預期將用于其他侯選產品; 3、約351.5百萬港元(占所得款項凈額的16.0%)預期將用于潛在管線產品; 4、約219.7百萬港元(占所得款項凈額的10.0%)預期將用于營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893
Joint Bookrunners (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SPDB International Capital Limited CE BFZ375 Mirae Asset Securities (HK) Limited CE BJB333 中银国际亚洲有限公司 CE AET863
Joint Lead Managers (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 UBS Securities Hong Kong Limited CE BIN466 中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SPDB International Capital Limited CE BFZ375 Mirae Asset Securities (HK) Limited CE BJB333 中银国际亚洲有限公司 CE AET863

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Aranda Investments Pte. Ltd. 38,746,400 HKD — 1.67% — 6 months 2021-05-03
2 AVICT Global Holdings Limited 116,239,200 HKD — 5.00% — 6 months 2021-05-03
3 Hillhouse Funds 77,492,800 HKD — 3.33% — 6 months 2021-05-03
4 LVC Mi Holding Limited 77,492,800 HKD — 3.33% — 6 months 2021-05-03
5 Oaktree Funds 154,997,500 HKD — 6.67% — 6 months 2021-05-03
6 Platinum Investment Management Limited 154,997,500 HKD — 6.67% — 6 months 2021-05-03
7 Rock Springs Capital Master Fund LP 154,997,500 HKD — 6.67% — 6 months 2021-05-03
8 RWC Asset Advisors (US) LLC 154,997,500 HKD — 6.67% — 6 months 2021-05-03
9 Veritas Asset Management LLP 154,997,500 HKD — 6.67% — 6 months 2021-05-03
10 太平资产管理(香港)有限公司 77,492,800 HKD — 3.33% — 6 months 2021-05-03

Directors & Management

PositionChinese nameEnglish Name
Chairman李怡平—
Company Secretary梁雪穎—
No director data available.

Major Shareholders

Major Shareholders & Holdings主要股東包括Juno(19.91%)、Syracuse Cayman(12.90%)、WXAT HK(10.16%)、TLS Beta Pte. Ltd.(6.03%)、李醫生(5.79%)及CJW Therapeutics Investment Limited(5.20%)等。
About this page

This page shows JW Therap-B (02126) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect